Skip to main content
. 2021 Dec 24;15(1):126. doi: 10.3390/ma15010126

Figure 4.

Figure 4

The steps used for designing and testing a miRNA-based therapeutic approach for neurodegenerative diseases. Abnormally expressed miRNAs are detected in patients’ tissues. Synthetic miRNAs are designed to target genes of interest. Specific delivery systems are designed to enter cells. The administration of miRNAs is tested in biologic models.